The purpose of this study is to provide access to CP-675,206 for patients with advanced unresectable melanoma and who have the potential to gain benefit from this treatment and who are not eligible for participation in other CP-675,206 studies.

This is an expanded access trial that canceled prior to enrolling patients.

Inclusion Criteria:

• Advanced melanoma with life expectancy of at least 6 months.
• Melanoma must be considered unresectable.
• Patients with stable, treated brain mets must be stable clinically and radiographically and off steroids for at least one month.

Exclusion Criteria:

• Patients must not be eligible for participation in any ongoing CP-675,206 clinical studies currently open for enrollment.
• History of chronic inflammatory or autoimmune disease.
• History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, active colitis, history of diverticulitis.